Brain volume loss in neuromyelitis optica spectrum disorder

2017 ◽  
Author(s):  
Jimena Miguez
Keyword(s):  
Neuromyelitis Optica ◽  
Brain Volume ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Volume Loss ◽  
Brain Volume Loss

scholarly journals Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

2021 ◽  
pp. jnnp-2021-326386
Author(s):  
Hiroki Masuda ◽  
Masahiro Mori ◽  
Shigeki Hirano ◽  
Akiyuki Uzawa ◽  
Tomohiko Uchida ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Brain Atrophy ◽  
Brain Volume ◽  
Spectrum Disorder ◽  
Aquaporin 4 ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Atrophy Rate ◽  
Matter Volume ◽  
Aquaporin 4 Antibody ◽  
Cord Lesion

ObjectiveTo investigate longitudinal brain atrophy in patients with neuromyelitis optica spectrum disorder (NMOSD).MethodsWe investigated the longitudinal brain atrophy rate in patients with aquaporin-4 antibody-positive NMOSD (AQP4+NMOSD) and those with multiple sclerosis (MS) in a retrospective cohort study. Brain volume was calculated with statistical parametric mapping-12.ResultsWe enrolled 36 patients with AQP4+NMOSD and 60 with MS. Patients with NMOSD were older and had a higher Kurtzke’s expanded disability status scale score at baseline MRI compared with those with MS. Disease duration, annual relapse rate and intervals from the last attack and from disease-modifying drugs initiation were not significantly different between the two groups. Lower normalised lesion volume and higher normalised white matter volume were found in patients with NMOSD compared with those with MS at baseline MRI. However, the annualised atrophy rate of normalised brain volume was similar between the NMOSD (median 0.47; IQR 0.75; p=0.49) and MS (median 0.46; IQR 0.84) groups. After adjustment of age and the presence of clinical relapse, no differences of the annualised atrophy rate of normalised brain volume also were found for NMOSD and MS. Patients with AQP4+NMOSD with long cord lesion showed higher annualised atrophy rate of normalised grey matter volume compared with those without long cord lesion.ConclusionsSilent progression of brain atrophy was present in patients with AQP4+NMOSD, as shown in patients with MS, even in the clinically inactive age-matched cases. Subclinical dying back degeneration may explain the brain atrophy in patients with AQP4 +NMOSD.

scholarly journals Neuromyelitis optica spectrum disorder with deafness and an extensive brainstem lesion

Heliyon ◽  
2021 ◽  
Vol 7 (1) ◽  
pp. e06106
Author(s):  
Asako Onda ◽  
Mikihiro Yamazaki ◽  
Takashi Shimoyama ◽  
Hiroshi Yaguchi
Keyword(s):  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Brainstem Lesion

Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study

2021 ◽  
Vol 204 ◽  
pp. 106606
Author(s):  
Samaneh Haji Molla Rabi ◽  
Shaghayegh Shahmirzaei ◽  
Mohammad Ali Sahraian ◽  
Razieh Sadat Kazemi Mozdabadi ◽  
Hossein Rezaei Aliabadi ◽  
...  
Keyword(s):  
Sleep Disorders ◽  
Neuromyelitis Optica ◽  
Case Control Study ◽  
Case Control ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Control Study

scholarly journals The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhila Maghbooli ◽  
Abdorreza Naser Moghadasi ◽  
Nasim Rezaeimanesh ◽  
Abolfazl Omidifar ◽  
Tarlan Varzandi ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Neuromyelitis Optica ◽  
Serum Levels ◽  
Spectrum Disorder ◽  
Control Group ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Downstream Signaling ◽  
Reduce Insulin Sensitivity ◽  
Circulating Levels

Abstract Background Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity. Methods We aimed to determine the risk association of hyperinsulinemia in NMOSD patients with seropositive AQP4-IgG and the serum levels of interleukin (IL)-6 and IL-17A compared with the control group. Serum levels of metabolic (Insulin, Fasting Blood Sugar (FBS), lipid profile) and inflammatory (IL-6 and IL-17) markers were assessed in 56 NMOSD patients and 100 controls. Results Hyperinsulinemia was more prevalent in NMOSD patients independent of age, sex and body mass index (BMI) (48.2% vs. 26%, p = 0.005) compared to control group. After adjusting age, sex and BMI, there was significant association between lower insulin sensitivity (IS) and NMOSD risk (95% CI: Beta = 0.73, 0.62 to 0.86, p = 0.0001). Circulating levels of IL-6 and IL-17 were higher in NMOSD patients, and only IL-6 had an effect modifier for the association between lower insulin sensitivity and NMOSD risk. Conclusions Our data suggests that inflammatory pathogenesis of NMOSD leads to hyperinsulinemia and increases the risk of insulin resistance.

scholarly journals COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America

2021 ◽  
Vol 51 ◽  
pp. 102886
Author(s):  
Ricardo Alonso ◽  
Berenice Silva ◽  
Orlando Garcea ◽  
Patricio E. Correa Diaz ◽  
Giordani Rodrigues dos Passos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder
Sign in / Sign up

Export Citation Format

Share Document